All In Biotech

Free tool

FAERS Monitor: Cystagon

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020392 or its brand name (Cystagon, Cysteamine Bitartrate). Reports on generic versions are filed under their own applications.

Reports

350

Serious

237

68% of reports

Hospitalization

139

Death reported

34

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting38
  • diarrhoea22
  • nausea21
  • off label use21
  • eye irritation17
  • abdominal pain15
  • treatment noncompliance15
  • eye pain14
  • headache14
  • pneumonia12
  • abdominal pain upper11
  • decreased appetite11
  • ocular hyperaemia11
  • product odour abnormal10
  • visual impairment10

Reports by year received

View as table
YearReports
200410
20052
20064
20076
20087
20092
20107
20117
20127
20131
201426
201511
201610
201724
201826
201924
202026
202117
202242
202333
202429
202522
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,809 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product odour abnormalSignal1057.431.2499
eye irritationSignal1717.811.2253
treatment noncomplianceSignal1516.510.0203
eye painSignal1414.98.9169
ocular hyperaemiaSignal1113.97.8120
vomitingSignal384.93.6115
visual impairmentSignal104.82.627
abdominal painSignal153.92.430
abdominal pain upperSignal113.21.815
decreased appetiteSignal112.81.612
pneumoniaSignal122.21.37
diarrhoeaSignal222.01.411
nausea211.61.14
off label use211.41.03
headache141.30.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.